Your browser is no longer supported. Please, upgrade your browser.
ADMA ADMA Biologics, Inc. daily Stock Chart
ADMA Biologics, Inc.
Index- P/E- EPS (ttm)-0.87 Insider Own0.50% Shs Outstand87.70M Perf Week0.55%
Market Cap168.36M Forward P/E- EPS next Y-0.46 Insider Trans12.11% Shs Float70.91M Perf Month-14.08%
Income-66.90M PEG- EPS next Q-0.16 Inst Own54.40% Short Float18.24% Perf Quarter-33.45%
Sales40.30M P/S4.18 EPS this Y38.90% Inst Trans-4.97% Short Ratio4.21 Perf Half Y-44.38%
Book/sh0.81 P/B2.26 EPS next Y45.90% ROA-37.20% Target Price- Perf Year-59.96%
Cash/sh0.65 P/C2.82 EPS next 5Y- ROE-98.80% 52W Range1.45 - 4.95 Perf YTD-54.25%
Dividend- P/FCF- EPS past 5Y13.30% ROI- 52W High-63.03% Beta1.82
Dividend %- Quick Ratio4.20 Sales past 5Y37.80% Gross Margin-33.70% 52W Low26.21% ATR0.10
Employees313 Current Ratio8.50 Sales Q/Q43.10% Oper. Margin- RSI (14)40.14 Volatility4.11% 5.11%
OptionableYes Debt/Eq1.36 EPS Q/Q0.00% Profit Margin- Rel Volume0.51 Prev Close1.85
ShortableYes LT Debt/Eq1.36 EarningsNov 05 AMC Payout- Avg Volume3.07M Price1.83
Recom1.70 SMA20-5.18% SMA50-15.09% SMA200-32.11% Volume1,701,586 Change-1.08%
Jun-04-19Initiated Jefferies Buy $8
Apr-15-19Reiterated H.C. Wainwright Buy $10 → $13
Feb-07-19Resumed H.C. Wainwright Buy $10
Dec-11-17Reiterated Maxim Group Buy $13 → $8
Nov-14-17Upgrade Raymond James Mkt Perform → Outperform
Jan-23-17Upgrade Maxim Group Hold → Buy $13
Aug-01-16Downgrade Maxim Group Buy → Hold
Jul-25-16Reiterated Maxim Group Buy $24 → $14
May-13-15Reiterated Maxim Group Buy $18 → $24
Dec-08-14Initiated Oppenheimer Outperform $20
Dec-01-14Reiterated Maxim Group Buy $16 → $18
Nov-10-20 07:00AM  
Nov-07-20 07:11AM  
Nov-06-20 09:31AM  
Nov-05-20 06:55PM  
Oct-29-20 07:00AM  
Oct-28-20 12:55PM  
Oct-21-20 07:00AM  
Oct-14-20 08:43AM  
Oct-07-20 09:16AM  
Oct-06-20 10:29AM  
Oct-01-20 08:41AM  
Sep-14-20 11:56AM  
Sep-09-20 07:00AM  
Sep-08-20 06:41AM  
Sep-03-20 07:00AM  
Sep-02-20 07:00AM  
Aug-25-20 08:55AM  
Aug-24-20 01:30PM  
Aug-10-20 01:03PM  
Aug-05-20 07:25PM  
Aug-03-20 07:34AM  
Jul-29-20 07:00AM  
Jul-07-20 08:55AM  
Jul-06-20 07:00AM  
Jul-03-20 10:13AM  
Jun-23-20 12:49PM  
Jun-09-20 03:21PM  
Jun-01-20 09:44AM  
May-27-20 07:00AM  
May-21-20 07:00AM  
May-07-20 10:30AM  
May-06-20 08:15PM  
May-01-20 06:13AM  
Apr-29-20 07:00AM  
Apr-03-20 03:48AM  
Mar-17-20 06:12AM  
Mar-12-20 04:05PM  
Mar-05-20 06:59AM  
Mar-03-20 07:00AM  
Feb-24-20 07:00AM  
Feb-13-20 05:07AM  
Feb-11-20 04:20PM  
Feb-07-20 07:32AM  
Feb-06-20 08:41PM  
Jan-09-20 07:00AM  
Jan-07-20 07:00AM  
Dec-23-19 05:36AM  
Dec-17-19 07:08AM  
Dec-14-19 08:04PM  
Nov-13-19 07:08AM  
Nov-08-19 05:33AM  
Nov-06-19 05:02PM  
Nov-04-19 07:08AM  
Oct-28-19 03:05PM  
Oct-22-19 07:48AM  
Oct-21-19 07:48AM  
Oct-17-19 07:29AM  
Oct-09-19 11:08AM  
Oct-07-19 07:08AM  
Oct-03-19 07:08AM  
Sep-23-19 07:08AM  
Sep-09-19 02:54PM  
Aug-22-19 07:48AM  
Aug-08-19 07:51AM  
Jul-08-19 08:22AM  
Jun-27-19 09:30AM  
Jun-18-19 04:35PM  
Jun-06-19 07:25AM  
May-30-19 06:14PM  
May-29-19 07:11AM  
May-24-19 10:30AM  
May-21-19 04:20PM  
May-16-19 08:00AM  
May-15-19 04:35PM  
May-10-19 06:58AM  
May-08-19 07:03PM  
Apr-17-19 07:08AM  
Apr-03-19 08:19AM  
Apr-02-19 06:58PM  
ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DEMSKI MARTHA JDirectorSep 11Buy2.292,2005,0384,200Sep 14 08:00 AM
Grossman Jerrold BDirectorSep 10Buy2.225,00011,100160,864Sep 11 08:00 AM
Mond JamesEVP, CSO and CMOSep 08Buy2.204,0008,80073,174Sep 10 08:01 AM
Grossman Adam SPresident and CEOSep 08Buy2.244,0008,960176,098Sep 10 08:00 AM
Grossman Jerrold BDirectorAug 21Buy2.565,30013,586155,864Aug 25 08:00 AM
DEMSKI MARTHA JDirectorAug 13Buy2.882,0005,7602,000Aug 14 08:00 AM
Grossman Jerrold BDirectorAug 12Buy2.8910,20029,499150,564Aug 13 08:01 AM
LENZ BRIANEVP, CFOAug 11Buy2.974,00011,86076,142Aug 12 08:02 AM
Grossman Adam SPresident and CEOAug 11Buy2.971,0002,970172,098Aug 12 08:02 AM
Grossman Adam SPresident and CEOAug 10Buy3.065,00015,290171,098Aug 12 08:02 AM
Mond JamesEVP, CSO and CMOAug 10Buy2.887,00020,15069,174Aug 12 08:01 AM
PERCEPTIVE ADVISORS LLC10% OwnerMar 19Buy2.10500,0001,050,00016,584,802Mar 23 08:30 AM
PERCEPTIVE ADVISORS LLC10% OwnerFeb 11Buy3.504,563,70015,972,95016,084,802Feb 11 08:02 AM
Guiheen Lawrence P.DirectorFeb 11Buy3.5020,00070,00070,000Feb 11 10:18 AM
Mond JamesCSO and CMOFeb 11Buy3.504,28514,99822,174Feb 11 10:16 AM
Grossman Jerrold BDirectorFeb 11Buy3.5022,85780,00022,857Feb 11 10:15 AM
Grossman Jerrold BDirectorFeb 11Buy3.5022,85780,000132,864Feb 11 10:15 AM
LENZ BRIANEVP, CFOFeb 11Buy3.507,14224,99732,142Feb 11 10:13 AM
Grossman Adam SPresident and CEOFeb 11Buy3.5057,143200,001878,444Feb 11 10:11 AM
Grossman Adam SPresident and CEOFeb 11Buy3.5028,57199,99966,098Feb 11 10:11 AM
CMRX Chimerix, Inc. daily Stock Chart
Chimerix, Inc.
Index- P/E- EPS (ttm)-0.57 Insider Own0.20% Shs Outstand62.24M Perf Week9.50%
Market Cap224.17M Forward P/E- EPS next Y-0.38 Insider Trans-10.89% Shs Float51.15M Perf Month34.67%
Income-35.40M PEG- EPS next Q-0.20 Inst Own53.10% Short Float2.22% Perf Quarter31.79%
Sales11.00M P/S20.38 EPS this Y-41.90% Inst Trans3.01% Short Ratio2.74 Perf Half Y18.27%
Book/sh1.34 P/B2.75 EPS next Y47.90% ROA-33.50% Target Price- Perf Year71.63%
Cash/sh1.44 P/C2.56 EPS next 5Y- ROE-36.50% 52W Range1.19 - 3.88 Perf YTD81.77%
Dividend- P/FCF- EPS past 5Y-2.40% ROI-105.20% 52W High-5.02% Beta1.86
Dividend %- Quick Ratio12.20 Sales past 5Y25.40% Gross Margin- 52W Low210.08% ATR0.22
Employees43 Current Ratio12.20 Sales Q/Q-20.00% Oper. Margin- RSI (14)66.26 Volatility7.63% 7.39%
OptionableYes Debt/Eq0.00 EPS Q/Q85.50% Profit Margin- Rel Volume0.44 Prev Close3.76
ShortableYes LT Debt/Eq0.00 EarningsNov 05 BMO Payout- Avg Volume415.07K Price3.69
Recom2.30 SMA2016.22% SMA5026.63% SMA20041.15% Volume185,235 Change-1.86%
Feb-14-18Downgrade JP Morgan Neutral → Underweight
Feb-02-18Initiated H.C. Wainwright Buy $10
Aug-09-16Reiterated FBR Capital Mkt Perform $9 → $8
Feb-23-16Reiterated FBR Capital Mkt Perform $14 → $10
Feb-23-16Downgrade Morgan Stanley Equal-Weight → Underweight
Feb-23-16Downgrade Barclays Overweight → Equal Weight $12 → $6
Feb-22-16Downgrade Citigroup Buy → Neutral
Dec-29-15Downgrade JP Morgan Overweight → Neutral $65 → $15
Dec-28-15Reiterated Piper Jaffray Overweight $63 → $10
Dec-28-15Downgrade FBR Capital Outperform → Mkt Perform $73 → $14
Dec-17-15Initiated UBS Buy $55
Oct-05-15Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-03-15Initiated Citigroup Buy
Aug-18-15Initiated FBR Capital Outperform $73
Aug-06-15Reiterated Brean Capital Buy $50 → $57
May-11-15Reiterated Brean Capital Buy $45 → $50
Mar-04-15Initiated Barclays Overweight $55
Feb-12-15Reiterated Stifel Buy $47 → $57
Dec-31-14Reiterated Brean Capital Buy $33 → $45
Jul-08-14Resumed Brean Capital Buy $33
Nov-07-20 08:33AM  
Nov-06-20 05:50AM  
Nov-05-20 04:01PM  
Oct-29-20 07:00AM  
Oct-28-20 08:12AM  
Sep-13-20 10:21AM  
Sep-10-20 08:00AM  
Aug-10-20 08:25AM  
Aug-03-20 08:00AM  
Jul-15-20 12:22PM  
Jul-05-20 02:43PM  
Jun-22-20 07:00AM  
Jun-18-20 08:00AM  
May-28-20 08:00AM  
May-12-20 06:47AM  
May-07-20 10:25AM  
May-02-20 08:40AM  
Apr-29-20 07:00AM  
Apr-28-20 04:30PM  
Mar-26-20 08:18AM  
Mar-18-20 06:26AM  
Feb-28-20 12:00PM  
Feb-26-20 08:00AM  
Feb-25-20 07:00AM  
Feb-24-20 08:00AM  
Feb-18-20 08:00AM  
Feb-06-20 07:04AM  
Feb-05-20 11:52AM  
Jan-29-20 08:00AM  
Jan-03-20 11:30AM  
Dec-23-19 06:12AM  
Dec-16-19 01:04AM  
Dec-14-19 08:59PM  
Dec-10-19 07:30AM  
Dec-04-19 01:01AM  
Nov-22-19 12:02AM  
Nov-07-19 06:19AM  
Nov-05-19 07:00AM  
Nov-04-19 04:01PM  
Oct-29-19 08:00AM  
Oct-02-19 08:47AM  
Oct-01-19 08:10AM  
Sep-30-19 07:30PM  
Sep-27-19 08:00AM  
Aug-27-19 01:13PM  
Aug-08-19 09:35AM  
Aug-07-19 10:30AM  
Aug-05-19 07:55AM  
Jul-31-19 07:00AM  
Jul-12-19 03:07PM  
Jun-28-19 06:41PM  
May-17-19 08:18AM  
May-16-19 09:11AM  
May-09-19 09:25AM  
May-02-19 04:01PM  
Apr-29-19 10:31AM  
Apr-12-19 01:43PM  
Apr-09-19 11:21AM  
Apr-08-19 05:00PM  
Apr-05-19 02:14PM  
Mar-26-19 06:30PM  
Mar-07-19 12:24PM  
Mar-05-19 07:00AM  
Mar-04-19 08:00AM  
Feb-26-19 08:00AM  
Feb-22-19 08:00AM  
Feb-14-19 08:15AM  
Feb-11-19 07:55AM  
Feb-06-19 02:20PM  
Jan-30-19 11:51AM  
Jan-24-19 10:17AM  
Jan-18-19 06:36AM  
Jan-17-19 09:38AM  
Jan-04-19 07:30AM  
Dec-27-18 09:23AM  
Dec-22-18 04:43AM  
Dec-18-18 08:35AM  
Dec-12-18 11:26AM  
Dec-03-18 07:55AM  
Nov-08-18 07:44AM  
Nov-07-18 08:14AM  
Nov-05-18 02:29PM  
Nov-01-18 08:00AM  
Oct-27-18 01:00PM  
Oct-24-18 07:25AM  
Oct-11-18 04:01PM  
Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include dociparstat sodium (DSTAT), a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of key proteins implicated in the retention and viability of acute myeloid leukemia blasts and leukemic stem cells in the bone marrow during chemotherapy; and brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications; and University of Michigan to research, develop, manufacture, and commercialize various products. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DEMSKI MARTHA JDirectorNov 17Option Exercise2.357,04216,5497,042Nov 19 12:57 PM
Jakeman DavidPrincipal Accounting OfficerOct 02Sale2.484,27010,59085,117Oct 02 04:06 PM
Meyer Robert J.DirectorAug 19Buy2.923,50010,22013,500Aug 19 05:34 PM
DEMSKI MARTHA JDirectorAug 10Option Exercise3.161,5845,0051,584Aug 11 05:49 PM
DEMSKI MARTHA JDirectorAug 10Sale3.251,5845,1480Aug 11 05:49 PM
DEMSKI MARTHA JDirectorAug 07Option Exercise3.162,5007,9002,500Aug 10 05:54 PM
DEMSKI MARTHA JDirectorAug 07Sale3.252,5008,1250Aug 10 05:54 PM
DEMSKI MARTHA JDirectorAug 06Option Exercise3.162,5007,9002,500Aug 10 05:54 PM
DEMSKI MARTHA JDirectorAug 06Sale3.292,5008,2240Aug 10 05:54 PM
DEMSKI MARTHA JDirectorAug 05Option Exercise3.162,5007,9002,500Aug 06 12:55 PM
DEMSKI MARTHA JDirectorAug 05Sale3.272,5008,1870Aug 06 12:55 PM
DEMSKI MARTHA JDirectorAug 04Option Exercise3.165,00015,8005,000Aug 06 12:55 PM
DEMSKI MARTHA JDirectorAug 04Sale3.255,00016,2500Aug 06 12:55 PM
Andriole Michael T.Chief Business OfficerMar 16Buy1.4333,30047,522149,729Mar 17 11:58 AM
MIDDLETON FRED ADirectorMar 12Buy1.4050,00069,900197,523Mar 16 12:19 PM
Sherman Michael A.Chief Executive OfficerMar 12Buy1.4572,995105,653102,995Mar 16 12:51 PM
Nichols GarrettChief Medical OfficerFeb 10Sale1.688,80514,830260,066Feb 11 04:19 PM
Nichols GarrettChief Medical OfficerFeb 07Sale1.702,5504,335268,871Feb 11 04:19 PM
Jakeman DavidPrincipal Accounting OfficerFeb 07Sale1.702,2903,89387,876Feb 11 04:16 PM
Nichols GarrettChief Medical OfficerJan 07Sale2.1530,68066,045271,421Jan 08 08:18 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.